Compare MBIN & ATAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MBIN | ATAI |
|---|---|---|
| Founded | 1990 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 2.7B |
| IPO Year | 2017 | 2025 |
| Metric | MBIN | ATAI |
|---|---|---|
| Price | $53.42 | $7.42 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 8 |
| Target Price | ★ $43.67 | $15.88 |
| AVG Volume (30 Days) | 147.0K | ★ 8.7M |
| Earning Date | 04-28-2026 | 05-11-2026 |
| Dividend Yield | ★ 0.89% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 2.73 | N/A |
| Revenue | N/A | ★ $4,089,000.00 |
| Revenue This Year | $31.76 | N/A |
| Revenue Next Year | $3.73 | N/A |
| P/E Ratio | $19.60 | ★ N/A |
| Revenue Growth | N/A | ★ 1227.60 |
| 52 Week Low | $30.37 | $3.27 |
| 52 Week High | $56.87 | $7.37 |
| Indicator | MBIN | ATAI |
|---|---|---|
| Relative Strength Index (RSI) | 52.83 | N/A |
| Support Level | $52.89 | N/A |
| Resistance Level | $56.87 | N/A |
| Average True Range (ATR) | 1.23 | 0.00 |
| MACD | -0.29 | 0.00 |
| Stochastic Oscillator | 9.66 | 0.00 |
Merchants Bancorp is a United States-based bank holding company operating multiple lines of business focused on FHA multi-family housing and healthcare facility financing and servicing, retail and correspondent residential mortgage banking, and traditional community banking. Its segments include Multi-family Mortgage Banking, which originates and services government-sponsored mortgages for multi-family and healthcare facilities; Mortgage Warehousing, which offers mortgage warehouse financing, commercial loans and deposit services; and the Banking segment, which generates maximum revenue and provides portfolio lending for multi-family and healthcare facility loans, residential mortgage banking, agricultural lending, SBA lending and community banking.
AtaiBeckley Inc is a clinical-stage biopharmaceutical company on a mission to transform patient outcomes by developing effective, rapid-acting, and convenient mental health treatments. AtaiBeckley's pipeline of novel therapies includes BPL-003 (mebufotenin benzoate nasal spray) for treatment-resistant depression (TRD), VLS-01 (DMT buccal film) for TRD, and EMP-01 ((R)-MDMA HCI) for social anxiety disorder, which are in Phase 2 clinical development.